Investigational TIL cell therapy is being studied in clinical trials in 3 steps:
Step 1: Preparative Regimen
The patient receives non-myeloablative lymphodepletion to reduce the suppressive environment.1,2
Step 2: TIL Infusion
Patients receive investigational TIL cell therapy.2
Step 3: IL-2 Infusion
A short course of IL-2 is administered to support T-cell activity.2
TIL cell therapy is being investigated in patients with various types of solid tumors.2
FDA=Food and Drug Administration; IL-2=interleukin-2; MHC-1=major histocompatibility complex-1; TIL=tumor infiltrating lymphocytes.
References: 1. Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656-2666. 2. Wardell S, Lienlaf-Moreno M, Blaskovich M, et al. Iovance Gen 2 TIL manufacturing process produces drug products that exhibit favorable quality attributes for adoptive cell transfer across 5 solid tumor indications. Poster P226 presented at: SITC Annual Meeting; November 6-10, 2019; National Harbor, MD.
Iovance Biotherapeutics 825 Industrial Road, Suite 400
San Carlos, CA 94070